MPTP/MPP＋诱导神经元凋亡的机制研究

1982年人们发现1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）能诱发PD,它的有效成分是1-甲基-4-苯基吡啶离子（MPP＋）。目前,MPTP/MPP＋广泛的被用作诱导PD实验模型的有效药物,可诱导神经元细胞发生凋亡性死亡。MPTP/MPP＋诱导细胞凋亡的机制牵涉Bcl-2、p53、caspase家族、JNK通路、ERK通路和PARP等多种机制,它们共同参与了MPTP/MPP＋诱导的细胞凋亡的调控和执行阶段。本文主要综述MPTP/MPP＋诱导的神经元细胞凋亡机制。     

MPTP诱导的帕金森病鼠脑内Calbindin-D28k表达的免疫组化研究

目的探讨Calbindin-D28k在帕金森病发病过程中的作用.方法健康C57BL/6J小鼠采用MPTP腹腔注射建立帕金森病动物模型,动物存活期分别为14d和28d.应用ABC免疫组化结合图像分析技术观察Calbindin-D28k在不同脑区的表达.结果帕金森病鼠脑内黑质和腹侧被盖区Calbindin-D28k的表达在28d比对照组增加,造模后海马CA1区Calbindin -D28k的表达在14d和28d两个时间点均比对照组增加;而在脑皮质Calbindin-D28k的表达在造模14d和28d均较对照组降低.结论不同脑区神经元可能由于Calbindin- D28k含量的不同而对MPTP的敏感性不同;帕金森病鼠不同脑区Calbindin- D28k表达的变化,可能是脑内神经元启动自我保护机制引起Calbindin- D28k在不同脑区重新分配,以达到保护损伤神经元的目的.     

蝎毒耐热蛋白对MPTP诱导的帕金森病小鼠脑内小胶质细胞的影响

目的：进一步探讨蝎毒耐热蛋白（SVHRP）改善MPTP（1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,MPTP）小鼠伴有空间学习记忆障碍的机制。方法：给予C57BL／6小鼠颈部皮下注射MPTP（20mg／kg）,连续8d,同时设立SVHRP治疗纽,观察小胶质细胞免疫反应活性的改变。结果：与盐水对照组相比,MPTP小鼠脑区OX-42免疫反应阳性小胶质细胞免疫反应活性明显增强。模型给药组与模型组相比OX-42免疫反应阳性小胶质细胞免疫反应活性明显降低。结论：SVHRP可以抑制MPTP诱发的小鼠脑内小胶质细胞的激活以减轻脑内神经炎症。     

MPTP对小鼠帕金森病造模条件探讨

目的观察不同剂量1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)对小鼠行为学及脑黑质酪氨酸羟化酶、纹状体多巴胺含量的影响,探讨MPTP致帕金森病(Parkinson′s disease,PD)样小鼠模型的最佳条件。方法C57BL小鼠分别给与MPTP不同剂量处理,测定各组小鼠爬竿时间检测动物运动协调性,应用免疫组化方法和高效液相法观察不同模型组多巴胺能神经元的变化。结果模型组各组均出现不同程度爬竿时间延长,酪氨酸羟化酶阳性细胞数减少和多巴胺含量减少。结论MPTP处理可造成小鼠的帕金森病样症状,在此种动物模型中,应根据科研目的选择MPTP的应用剂量和给药途径。     

骨髓基质干细胞对MPP+制备的PC12细胞凋亡的影响

目的探讨BMSCs分泌物对MPP^＋诱导的PC12细胞凋亡的保护作用。方法在体外培养、纯化BMSCs并收集其培养上清,流式细胞术分析PC12细胞的凋亡率;通过免疫细胞化学法和RT-PCR法检测PC12细胞bcl-2和TH在蛋白和mRNA水平的表达。结果BMSCs可在体外分离扩增,其表面抗原CD44阳性而CD45阴性,流式细胞术检测显示BMSCs上清液组加MPP^＋处理组（联合组）细胞凋亡率低于MPP^＋损害组;免疫细胞化学法和RT-PCR法显示联合组的bcl-2和TH蛋白和mRNA水平与MPP^＋损害组相比明显增加。结论BMSCs能分泌多种对退变多巴胺能神经元有保护作用的神经营养因子,因此BMSCs对MPP^＋诱导的PC12细胞凋亡有保护作用,其保护作用的强弱与BMSCs上清液浓度有关,其作用机制可能是通过上调bcl-2来实现的。     

MPTP帕金森病动物模型研究进展

用神经毒素1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)制备的动物模型,无论在神经生化和病理组织学特征,还是在运动行为表现方面都酷似人帕金森病(PD),是目前研究PD的理想模型。对MPTP动物模型发病机制等方面的深入研究将有助于PD的防治。     

CUL1基因对MPP+诱导的SH-SY5Y细胞存活和NLRP3炎症体通路的影响

摘要 目的：探究Cullin1（CUL1）基因对1-甲基-4-苯基吡啶离子（MPP+）诱导的SH-SY5Y细胞存活和核苷酸结合寡聚化结构域样受体3（NLRP3）炎症体通路的影响。方法：（1）将SH-SY5Y细胞分为NC组、NC-sh组、CUL1-sh组、NC-OE组和CUL1-OE组。使用Lipofectamine 2000试剂对细胞转染相应的慢病毒。（2）将SH-SY5Y细胞分为Control组、MPP+组和MPP++CUL1-OE组。MPP+组和MPP++CUL1-OE组细胞使用1 mmol/L的MPP+处理48 h,Control组细胞正常培养。通过MTT法检测细胞增殖,通过Annexin V-FITC/PI双染色法和TUNEL染色法检测细胞凋亡,通过qRT-PCR检测CUL1的mRNA水平,通过Western blot检测CUL1、NLRP3、凋亡相关斑点样蛋白（ASC）、cleaved caspase-1、白细胞介素（IL）-1β和IL-18蛋白水平。通过ELISA法检测细胞培养上清液中IL-1β和IL-18水平。结果：（1）与NC组和NC-sh组比较,CUL1-sh组CUL1的mRNA和蛋白相对表达量降低,相对细胞活力降低,Annexin V-FITC/PI阳性率和TUNEL阳性率升高,NLRP3、ASC、cleaved caspase-1、IL-1β和IL-18蛋白相对表达量以及细胞培养上清液中IL-1β和IL-18水平升高（P<0.05）。与NC组和NC-OE组比较,CUL1-OE组CUL1的mRNA和蛋白相对表达量升高,相对细胞活力升高,Annexin V-FITC/PI阳性率和TUNEL阳性率降低,NLRP3、ASC、cleaved caspase-1、IL-1β和IL-18蛋白相对表达量以及细胞培养上清液中IL-1β和IL-18水平降低（P<0.05）。（2）与Control组比较,MPP+组CUL1的mRNA和蛋白相对表达量降低,相对细胞活力降低,Annexin V-FITC/PI阳性率和TUNEL阳性率升高,NLRP3、ASC、cleaved caspase-1、IL-1β和IL-18蛋白相对表达量以及细胞培养上清液中IL-1β和IL-18水平升高（P<0.05）。与MPP+组比较,MPP++CUL1-OE组CUL1的mRNA和蛋白相对表达量升高,相对细胞活力升高,Annexin V-FITC/PI阳性率和TUNEL阳性率降低,NLRP3、ASC、cleaved caspase-1、IL-1β和IL-18蛋白相对表达量以及细胞培养上清液中IL-1β和IL-18水平降低（P<0.05）。结论：CUL1可能通过抑制NLRP3炎症体激活促进MPP+诱导的SH-SY5Y细胞存活。     

帕金森病小鼠模型行为学检测方法的比较研究

目的比较目前常用的5种帕金森病(PD)小鼠模型行为学检测方法在PD研究中的作用。方法用MPTP建立C57BL小鼠PD模型,通过行为学检测(自主活动计数、滚轴实验、游泳实验、爬杆实验、悬挂实验)、免疫组织化学和荧光分光光度法,对比5种行为学检测方法的平均数与变异系数,观察MPTP对PD小鼠模型的行为学、黑质多巴胺(DA)神经元和纹状体酪氨酸羟化酶免疫反应阳性(TH-ir)神经纤维以及纹状体DA水平的影响。结果给与MPTP后,小鼠行为学计数降低,爬杆实验未能得到检测结果,悬挂实验变异系数很高,结果有明显的偶然性,滚轴实验结果变异系数中等,平均数呈现一定的上升趋势,自主活动计数中移动与站立和游泳实验的平均数则呈现明显的下降趋势,变异系数很低,而黑质DA神经元数目减少约58%,纹状体TH-ir神经纤维密度减低,纹状体DA水平明显降低约88%,两组相比差异有显著性(P<0.01)。结论MPTP所致的C57BL小鼠的神经病理、生化改变与PD患者近似,自主活动计数和游泳实验优于其他行为学检测方法。     

单侧帕金森病猴模型的行为、神经递质、多巴胺受体、病理及局部脑血流研究

经右侧颈总动脉注射甲基-苯基-四氢吡啶(MPTP)使猴产生左侧肢体动作减少、行动迟缓、震颤及向右侧缓慢旋转。应用美多巴和阿朴吗啡显著地改善单侧帕金森病(PD)症状,同时引起向左侧快速旋转,并呈明显的剂量依赖性;应用苯丙胺引起向右侧快速旋转。连续应用美多巴诱致单侧PD猴产生舞蹈手足徐动症。高效液相色谱测定显示右侧壳核、尾状核和黑质多巴胺(DA)含量显著降低。光镜发现右侧黑质神经元变性。SPECT活体显像发现病损侧纹状体D_2DA受体活性在病损初期无改变,病损严重时超敏,以及病损侧脑血流灌注减低。实验表明MPTP可建成理想的能形象地模拟人类PD的单侧PD猴模型。SPECT是活体研究PD病理生理的有效检测手段。     

花生种子内源ABA含量变化及其与活力的关系

花生（Ａｒａｃｈｉｓ ｈｙｐｏｇａｅａ Ｌ．）种子发育过程中,胚轴内源ＡＢＡ 含量一直是增加的;种皮内源ＡＢＡ含量在果针入土后４０ ｄ 最大,然后急剧下降;子叶内源ＡＢＡ 含量在果针入土后６０ ｄ 出现高峰,然后有轻微下降。种子活力指数和萌发时内源ＡＢＡ 的净下降量有密切关系。甘露醇可促进离体胚内源ＡＢＡ 合成,１－甲基－３－苯基－５（３－［三氟甲基］－苯基－４－（１氢）－吡啶）抑制子叶内源ＡＢＡ 的合成,子叶和胚轴存在不同的ＡＢＡ 合成途径。种子早熟和早萌处理时,内源ＡＢＡ 含量都下降,胚轴在种子由发育向萌发转换中起着十分重要的作用     

Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B

The kinetics of the interactions of MPTP and its N-des-methyl-derivative (PTP) have been studied. Both were mechanism-based inhibitors as well as substrates for the enzyme. Analysis of the reaction progress-curves for the formation of the corresponding dihydropyridine derivatives allowed the kinetic parameters for the process and the partition ratio, which corresponds to the number of mol. of product formed per mol. of enzyme inactivated, to be determined for both compounds. The conversion of MPTP to its corresponding pyridinium-ion derivative through the action of MAO-B is known to be essential for its neurotoxicity. PTP has been reported not to be neurotoxic, although it appears to be a relatively good substrate for MAO-B as well as acting a mechanism-based inhibitor. Studies of the changes in absorbance spectra during the MAO-B catalysed oxidation were consistent with the formation of the corresponding pyridinium-ion derivative (MPP+), which is known to be the effective neurotoxin, as the end-product when MPTP was oxidized. In contrast the oxidation of PTP appeared to stop at the dihydropyridine stage with no significant further oxidation to the corresponding pyridine-derivative.     

The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor

Dysfunction of the microtubule system is emerging as a contributing factor in a number of neurodegenerative diseases. Looking for the potential role played by the microtubule cytoskeleton in neuron degeneration underlying Parkinson's disease (PD), we investigate the influence of the parkinsonism producing neurotoxin 1-methyl-4-phenylpyridinium (MPP+) on microtubule dynamics. We find that it acts as a strong catastrophe promoter causing a decrease of the average length of microtubules assembled from purified tubulin. We also find that it reduces the number of microtubules nucleated from purified centrosomes. Finally, binding assays demonstrate that the neurotoxin binds specifically to tubulin in the microtubule lattice in a close to stoichiometric manner. This paper provides the first evidence that dynamic instability of microtubules is specifically affected by MPP+ and suggests that it could play a role in neuronal cell death underlying PD.     

Studies on the Neurotoxicity of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine: Inhibition of NAD-Linked Substrate Oxidation by Its Metabolite, 1-Methyl-4-Phenylpyridinium

Abstract: The effects of the parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its 4-electron oxidation product 1-methyl-4-phenylpyridinium (MPP⁺) were studied in isolated mitochondria and in mouse brain striatal slices. ADP-stimulated oxidation of NAD-linked substrates was inhibited in a time-dependent manner by MPP⁺ (0.1–0.5 m M ), but not MPTP, in mitochondria prepared from rat brain, mouse brain, or rat liver. Under identical conditions, succinate oxidation was relatively unaffected. In neostriatal slices prepared from the mouse, a species susceptible to the dopaminergic neurotoxicity of MPTP, incubation with either MPP⁺ or MPTP caused metabolic changes consistent with inhibition of mitochondnial oxidation, i.e., an increase in the formation of lactate and accumulation of the amino acids glutamate and alanine with concomitant decreases in glutamine and aspartate levels. The changes resulting from incubation with MPTP were prevented by the monoamine oxidase inhibitor pargyline, which blocks formation of MPP⁺ from MPTP. The results suggest that compromise of mitochondrial function and its metabolic sequelae within dopaminergic neurons could be an important factor in the neurotoxicity observed after MPTP administration.     

1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3

1-Methyl-4-phenylpyridinium (MPP+), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, induces apoptosis in cerebellar granule neurons (CGNs). We have tested the hypothesis that organic cation transporter (OCT) 3 mediates the accumulation and, hence, the toxicity of MPP+ in CGNs. CGNs in primary culture express OCT3 but do not express mRNA for OCT1, OCT2 or the dopamine transporter. Cerebellar astrocytes are negative for OCT3 protein by immunocytochemistry. [3H]MPP+ accumulation by CGNs exhibits first-order kinetics, and a Kt value of 5.3 +/- 1.2 micro m and a Tmax of 0.32 +/- 0.02 pmol per min per 106 cells. [3H]MPP+ accumulation is inhibited by corticosterone, beta-estradiol and decynium 22 with Ki values of 0.25 micro m, 0.17 micro m and 4.0 nm respectively. [3H]MPP+ accumulation is also inhibited by desipramine, dopamine, serotonin and norepinephrine, but is not affected by carnitine (10 mm), mazindol (9 micro m) or GBR 12909 (1 micro m). MPP+-induced caspase-3-like activation and cell death are prevented by pretreatment with 5 micro mbeta-estradiol. In contrast, the neurotoxic effects of rotenone are unaffected by beta-estradiol. Interestingly, GBR 12909 protects CGNs from both MPP+ and rotenone toxicity. In summary, CGNs accumulate MPP+ in manner that is consistent with uptake via OCT3 and the presence of this protein in CGNs explains their sensitivity to MPP+ toxicity.     

Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion

Dimebon is an anti-histamine with central nervous system activity. In this report the effects of dimebon as a neuroprotectant in animal models of Parkinson's disease were tested as assessed in methamphetamine- and MPTP-induced striatal dopaminergic toxicity. Dimebon (1mg/kg) administered at 30 min prior to methamphetamine (40mg/kg) significantly reduced the amount of striatal dopamine depletion in mice, without altering the initial methamphetamine-induced increase in body temperature. In contrast, dimebon at either 1 or 25mg/kg administered at 30 min prior to MPTP (35 mg/kg) was unable to prevent MPTP-induced striatal dopamine loss as determined at 7 days post-methamphetamine/MPTP. These data suggest that dimebon may be exerting a neurotoxin specific neuroprotective effect upon the striatal dopaminergic system and may serve as an important tool for discriminating the mechanistic basis of these two dopaminergic neurotoxins.     

Potentiation by the Tetraphenylboron Anion of the Effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine and Its Pyridinium Metabolite

The 1-methyl-4-phenylpyridinium species (MPP+) is the four-electron oxidation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and is widely assumed to be the actual neurotoxic species responsible for the MPTP-induced destruction of dopaminergic neurons. MPTP is oxidized by the enzyme monoamine oxidase-B to a dihydropyridinium intermediate which is oxidized further to MPP+, an effective inhibitor of the oxidation of the Complex I substrates glutamate/malate in isolated mitochondrial preparations. In the present study, the tetraphenylboron anion (TPB) greatly potentiated the inhibitory effects of MPP+ and other selected pyridinium species on glutamate/malate respiration in isolated mouse liver mitochondria. At 10 microM TPB, the potentiation ranged from approximately 50-fold to greater than 1,000-fold for the several pyridinium species tested. In other experiments, TPB greatly enhanced the accumulation of [3H]MPP+ by isolated mitochondrial preparations. This facilitation by TPB of MPP+ accumulation into mitochondria explains, at least in part, the potentiation by TPB of the above-mentioned inhibition of mitochondrial respiration. Moreover, TPB addition increased the amount of lactate formed during the incubation of mouse neostriatal tissue slices with MPTP and other tetrahydropyridines. The administration of TPB also potentiated the dopaminergic neurotoxicity of MPTP in male Swiss-Webster mice. All of these observations, taken together, are consistent with the premise that the inhibitory effect of MPP+ on mitochondrial respiration within dopaminergic neurons is the ultimate mechanism to explain MPTP-induced neurotoxicity.     

Rapid down-regulation of Ret following exposure of dopaminergic neurons to neurotoxins

The survival and functional maintenance of vertebrate neurons depends on the availability of specific neurotrophic factors. We studied the influence of neurotrophic support on responses of dopaminergic neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a neurotoxin known to damage the nigrostriatal dopaminergic pathway in humans and other mammals. Treatment of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine caused decreases in levels of Ret, a tyrosine kinase receptor for glial cell line-derived neurotrophic factor (GDNF) in the striatum, under the condition in which tyrosine hydroxylase was moderately decreased and the GDNF family receptor alpha1, another receptor of GDNF that is the ligand-binding subunit, were unaffected. Down-regulation of Ret was also observed in dopamine-producing PC12 cells undergoing apoptosis induced by rotenone, another toxic substance for dopaminergic neurons, while other cellular components were not affected. Ret was also extremely vulnerable to other apoptotic inducing conditions. Taken together, these results indicate that Ret, an important signal molecule in dopaminergic neurons, may be down-regulated in the early stages of neuronal degeneration caused by various neurotoxic substances, and may lead to reduced neurotrophic influences.     

Evaluation of the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to toxic pyridinium cations by monoamine oxidase (MAO) enzymes and its use to search for new MAO inhibitors and protective agents

Monoamine oxidase (MAO) enzymes catalyze the oxidative deamination of amines and neurotransmitters and inhibitors of MAO are useful as neuroprotectants. This work evaluates the human MAO-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin, to the directly-acting neurotoxic metabolites, 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP⁺) and 1-methyl-4-phenylpyridinium (MPP⁺) measured by High-Performance Liquid Chromatography (HPLC), and this approach is subsequently used as a new method for screening of MAO inhibitors and protective agents. Oxidation of MPTP by human MAO-B was more efficient than by MAO-A. R-Deprenyl, a known neuroprotectant, norharman (β-carboline), 5-nitroindazole and menadione (vitamin K3) inhibited MAO-B and reduced the formation of toxic pyridinium cations. Clorgyline and the β-carbolines, harman and norharman, inhibited the oxidation of MPTP by MAO-A. Cigarette smoke, as well as the naturally occurring β-carbolines (norharman and harman) isolated from smoke and coffee inhibited the oxidation of MPTP by MAO-B and/or MAO-A, suggesting protective effects against MPTP. The results show the suitability of the approach used to search for new MAO inhibitors with eventual neuroprotective activity.     

SIRT1 deficiency attenuates MPP+-induced apoptosis in dopaminergic cells

One of the functions mediated by sirtuin 1 (SIRT1), the NAD⁺-dependent protein deacetylase, has been suggested to be neuroprotective since resveratrol, a SIRT1 activator, inhibits 1-methyl-4-phenylpyridinium ion (MPP⁺)-induced cytotoxicity. In this study, we show that SIRT1 siRNA transfection blocks MPP⁺-induced apoptosis in SH-SY5Y cells. The ratio of potential pro-apoptotic BNIP2 to antiapoptotic BCL-xL was attenuated in SIRT1-deficient cells following MPP⁺ treatment. In addition, BNIP2 shRNA-transfected cells showed reduced cleavage of PARP-1, while BNIP2 overexpression intensified the cleavage in MPP⁺-treated SH-SY5Y cells, suggesting that BNIP2 participates in the MPP⁺-induced apoptosis. Overall, these data imply that SIRT1 may mediate MPP⁺-induced cytotoxicity, possibly through the regulation of BNIP2.